×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| HIKAL LTD. | 3814.0 | -227.0 | 3804.0 | -1.84 | 3,198 | 50.5 |
| SOLARA ACTIVE PHARMA SCIENCES | 3201.3 | 105.2 | 3191.5 | 2.46 | 3010 | 123.0 |
| PANACEA BIOTEC LTD. | 1172.0 | -67.0 | 1122.5 | -1.09 | 2762 |
Hikal Ltd., with Security Code 524735, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 545.3 | 388.1 | 434.9 | 447.6 | 514.1 | 406.8 | 452.9 | 447.7 | 552.4 | 380.4 |
| Expenses | 457.2 | 337.8 | 377.4 | 382.7 | 419.8 | 348.7 | 378.2 | 375.5 | 428.9 | 355.6 |
| Operating Profit | 88.1 | 50.2 | 57.5 | 64.9 | 94.4 | 58.1 | 74.7 | 72.2 | 123.5 | 24.8 |
| OPM % | 16.15% | 12.94% | 13.22% | 14.5% | 18.35% | 14.28% | 16.49% | 16.13% | 22.36% | 6.52% |
| Other Income | 0.4 | 0.9 | 1.0 | 0.1 | 0.5 | 0.5 | 0.4 | 3.6 | 0.5 | 1.0 |
| Interest | 13.0 | 13.8 | 13.1 | 14.2 | 15.3 | 19.8 | 18.8 | 18.7 | 17.9 | 17.1 |
| Depreciation | 26.8 | 27.7 | 28.6 | 29.0 | 32.3 | 31.8 | 31.7 | 33.2 | 37.7 | 39.4 |
| Profit before tax | 48.6 | 9.7 | 16.8 | 21.7 | 47.2 | 7.0 | 24.6 | 23.9 | 68.4 | -30.7 |
| Tax % | -25.9% | -28.9% | -25.5% | -25.2% | -28.3% | -25.7% | -26.4% | -27.6% | -26.5% | 26.1% |
| Net Profit | 36.1 | 6.9 | 12.5 | 16.3 | 33.9 | 5.2 | 18.1 | 17.3 | 50.3 | -22.7 |
| EPS in Rs | 2.93 | 0.56 | 1.02 | 1.32 | 2.75 | 0.42 | 1.47 | 1.4 | 0 | -1.84 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 540.2 | 545.3 | 388.1 | 434.9 | 447.6 | 514.1 | 406.8 | 452.9 | 447.7 | 552.4 |
| Expenses | 465.6 | 457.3 | 337.8 | 377.4 | 382.8 | 419.6 | 348.8 | 378.0 | 375.6 | 429.0 |
| Operating Profit | 74.6 | 88.0 | 50.3 | 57.5 | 64.8 | 94.5 | 58.0 | 74.9 | 72.1 | 123.4 |
| OPM % | 13.81% | 16.14% | 12.96% | 13.23% | 14.47% | 18.37% | 14.26% | 16.54% | 16.1% | 22.34% |
| Other Income | 2.5 | 0.4 | 0.9 | 1.0 | 0.1 | 0.5 | 0.5 | 0.4 | 3.6 | 0.5 |
| Interest | 13.0 | 13.0 | 13.8 | 13.1 | 14.2 | 15.3 | 19.8 | 18.8 | 18.7 | 17.9 |
| Depreciation | 28.3 | 26.8 | 27.7 | 28.6 | 29.0 | 32.3 | 31.8 | 31.7 | 33.2 | 37.7 |
| Profit before tax | 35.8 | 48.6 | 9.7 | 16.9 | 21.6 | 47.3 | 6.9 | 24.8 | 23.8 | 68.3 |
| Tax % | -26.2% | -25.9% | -28.7% | -25.4% | -25.3% | -28.2% | -26.1% | -26.2% | -27.7% | -26.5% |
| Net Profit | 26.4 | 36.0 | 6.9 | 12.6 | 16.1 | 34.0 | 5.1 | 18.3 | 17.2 | 50.2 |
| EPS in Rs | 2.14 | 2.92 | 0.56 | 1.02 | 1.31 | 2.76 | 0.41 | 1.48 | 1.39 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -1% |
| 3 Years: | -17% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 1% |
| 1 Year: | 35% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -1% |
| 3 Years: | -17% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 28% |
| 3 Years: | 1% |
| 1 Year: | 35% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|